| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PC; PDX; PCLP; Gp200; gp135; PCLP-1; PODXL1 |
| Entrez GeneID | 5420 |
| clone | 2H2G2 |
| WB Predicted band size | 58.6kda |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PODXL (AA: Extra(23-172)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于PODXL抗体的3篇示例性参考文献(注：文献为模拟示例，实际文献请通过学术数据库查询)：
---
1. **文献名称**：*Podocalyxin as a Prognostic Marker in Invasive Breast Cancer*
**作者**：Smith A et al.
**摘要**：研究通过免疫组化分析乳腺癌组织中PODXL的表达水平，发现其高表达与肿瘤转移和患者生存率降低显著相关，提示PODXL可作为乳腺癌不良预后的生物标志物。
---
2. **文献名称**：*PODXL Promotes Colorectal Cancer Metastasis via EMT Activation*
**作者**：Lee J et al.
**摘要**：通过体外和动物模型实验，证明PODXL通过调控上皮-间质转化(EMT)相关通路增强结直肠癌细胞迁移和侵袭能力，抗体阻断实验进一步验证其功能依赖性。
---
3. **文献名称**：*Diagnostic Utility of PODXL in Renal Cell Carcinoma*
**作者**：Garcia R et al.
**摘要**：探讨PODXL抗体在肾细胞癌病理诊断中的应用，发现其在区分肾癌亚型中的敏感性和特异性优于传统标记物，可能成为新型诊断工具。
---
如需具体文献，建议在PubMed或Web of Science中检索关键词“PODXL antibody”“podocalyxin cancer”等获取最新研究。
**Background of PODXL Antibody**
PODXL (Podocalyxin), a cell surface glycoprotein belonging to the CD34 family, plays critical roles in cell adhesion, polarity, and migration. Initially identified in kidney podocytes, where it helps maintain the glomerular filtration barrier, PODXL is also expressed in hematopoietic progenitors, vascular endothelial cells, and certain epithelial tissues. Its structure includes a heavily glycosylated extracellular domain, a transmembrane region, and a cytoplasmic tail that interacts with cytoskeletal linkers like ezrin, influencing cell shape and motility.
In cancer biology, PODXL is recognized as an oncofetal protein, often overexpressed in aggressive carcinomas (e.g., renal, breast, colorectal, and pancreatic cancers). Elevated PODXL correlates with poor prognosis, promoting tumor progression by enhancing invasiveness, metastasis, and resistance to apoptosis. It also serves as a potential cancer stem cell (CSC) marker, aiding in the identification of therapy-resistant subpopulations.
PODXL antibodies are essential tools in research and diagnostics. They enable the detection of PODXL expression in tissue samples via immunohistochemistry (IHC) or flow cytometry, aiding cancer subtyping and prognostic stratification. Therapeutically, anti-PODXL monoclonal antibodies or antibody-drug conjugates (ADCs) are under exploration to target PODXL-expressing malignancies. However, challenges remain, including understanding its context-dependent roles and optimizing specificity to minimize off-target effects.
Overall, PODXL antibodies hold promise for advancing cancer diagnostics and targeted therapies, though further studies are needed to fully exploit their clinical potential.
×
